The Cardiovascular Research Foundation (CRF) has announced that TVT 2019, the Structural Heart Summit, will feature four studies which will be presented as Late-Breaking Science on Friday, June 14th in the Sheraton Chicago Ballroom IV- VII from 3:00 PM to 4:00 PM. They include the following studies:
Outcomes Following Transcarotid Versus Transpical/Transaortic Access for Transcatheter Aortic Valve Replacement: Results from the Transcatheter Valve Therapy (TVT) Registry
Keith B. Allen
Compassionate Use of the PASCAL Transcatheter Valve Repair System for Severe Tricuspid Regurgitation: A Multicenter, Observational, First-in-Human Experience
Neil P. Fam
Hemodynamic Outcomes and Predictors of Prosthesis-Patient Mismatch After Transcatheter or Surgical Aortic Valve Replacement in Low-Risk Patients: Results from the Evolut Low-Risk Trial
Echocardiographic Results of Transcatheter Versus Surgical Aortic Valve Replacement in Low-Risk Patients: The PARTNER 3 Trial
TVT 2019 is a practical course featuring the latest research and state-of-the-art techniques for transcatheter aortic and mitral valve therapies. For more than 10 years, TVT has provided healthcare professionals with the latest advances, tools, and techniques for the treatment of valvular heart disease using nonsurgical procedures. The complete agenda is now available online at https:/
Additional course highlights include:
- Live Cases: 20 live case demonstrations of transcatheter aortic and mitral-tricuspid valve interventions, as well as LAA and PFO closures, from eight renowned U.S. and international sites.
- TVT Training Pavilion: 20 dynamic workshops including trans-septal techniques, MitraClip, imaging for TVT guidance, and new TAVR technologies.
- Case-Based Learning: Enhanced image-guided therapy workshops with case presentations and interactive discussions, plus unique "Bioskills" sessions on cardiac anatomy and transcatheter procedures with integrated echo and CT imaging and virtual reality.
- Innovation Sessions featuring the next generation of early stage technologies.
- Cardiovascular Team Professionals Symposium aimed at members of the Structural Heart Team.
- Moderated Poster Sessions highlighting more than 80 poster presentations.
Valvular heart disease affects a large number of people who require diagnostic procedures and long-term management. Many patients have no symptoms, but for others, if not treated, advanced heart valve disease can lead to heart failure, stroke, blood clots, or death due to sudden cardiac arrest. Traditionally, valvular heart disease has been treated with surgical repair or replacement. Over the last several years, there have been important advances in concepts, tools, techniques, and patient selection using nonsurgical procedures. Transcatheter valve intervention offers the potential to reduce the procedural morbidity, mortality, and costs of surgical valve replacement or repair while accelerating patient recovery.
June 12-15, 2019
Sheraton Grand Chicago
301 East North Water Street
Chicago, IL 60611
HOW TO REGISTER:
Media may apply for registration by emailing email@example.com.
The Cardiovascular Research Foundation (CRF) is a nonprofit research and educational organization dedicated to helping doctors improve survival and quality of life for people suffering from heart and vascular disease. For nearly 30 years, CRF has helped pioneer innovations in interventional cardiology and educated doctors on the latest treatments for heart disease. For more information, visit http://www.